Dicerna Pharmaceuticals (NASDAQ:DRNA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday, February 9th.
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
A number of other equities research analysts have also weighed in on the stock. SunTrust Banks began coverage on shares of Dicerna Pharmaceuticals in a report on Monday, February 5th. They issued a “buy” rating and a $13.00 price objective on the stock. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Chardan Capital reiterated a “neutral” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, January 16th. Finally, Evercore ISI started coverage on shares of Dicerna Pharmaceuticals in a research note on Tuesday, January 16th. They issued an “outperform” rating and a $14.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $10.05.
Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) traded up $0.57 on Friday, hitting $10.63. 414,700 shares of the stock were exchanged, compared to its average volume of 384,464. Dicerna Pharmaceuticals has a fifty-two week low of $2.52 and a fifty-two week high of $11.19.
In related news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were purchased at an average price of $7.00 per share, with a total value of $1,995,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 29.41% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of DRNA. RTW Investments LP raised its position in shares of Dicerna Pharmaceuticals by 142.2% in the fourth quarter. RTW Investments LP now owns 5,035,662 shares of the biopharmaceutical company’s stock valued at $44,142,000 after buying an additional 2,956,671 shares during the last quarter. Bridger Management LLC acquired a new position in shares of Dicerna Pharmaceuticals in the fourth quarter valued at approximately $8,181,000. First Manhattan Co. acquired a new position in shares of Dicerna Pharmaceuticals in the fourth quarter valued at approximately $3,865,000. Monashee Investment Management LLC acquired a new position in shares of Dicerna Pharmaceuticals in the fourth quarter valued at approximately $1,878,000. Finally, Deutsche Bank AG increased its position in Dicerna Pharmaceuticals by 225.8% during the fourth quarter. Deutsche Bank AG now owns 168,400 shares of the biopharmaceutical company’s stock worth $1,520,000 after purchasing an additional 116,719 shares during the last quarter. 24.60% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Dicerna Pharmaceuticals (DRNA) Downgraded to Sell at Zacks Investment Research” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/19/zacks-investment-research-lowers-dicerna-pharmaceuticals-drna-to-sell.html.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.